会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • METHODS AND COMPOSITIONS FOR DIAGNOSIS, STAGING AND PROGNOSIS OF PROSTATE CANCER
    • 前列腺癌的诊断,分期和预后的方法和组合
    • WO2005007830A2
    • 2005-01-27
    • PCT/US2004022850
    • 2004-07-14
    • MAYO FOUNDATIONVANAJA DONKENA KYOUNG CHARLES Y F
    • VANAJA DONKENA KYOUNG CHARLES Y F
    • C12N20060101C12Q1/68C12N
    • C12Q1/6886C12Q2600/112C12Q2600/154C12Q2600/158
    • The present invention provides, inter alia, novel methods and compositions for the diagnosis, staging and prognosis of prostate cancer, based on DNA methylation and/or modulation of gene expression, including transcriptional silencing. Preferred diagnostic and/or prognostic nucleic acid and protein markers include at least one of: the differentially (relative to benign tissue) down-regulated sequences corresponding to zinc finger protein 185 (ZNF 185), prostate secretory protein (PSP94), bullous pemphigoid antigen (BPAG), supervillin (SVIL), proline rich membrane anchor 1 (PRIMA1), TU3A, FLJ14084, KIAA1210, Sorbin and SH3 domain containing 1 (SORBS1), and C21orf63; and the differentially up-regulated sequences MARCKS-like protein (MLP) SRY (sex determining region Y)-box 4 (SOX4), fatty acid binding protein 5 (FABP5), MAL2, and Erg-2.
    • 本发明尤其提供了用于基于DNA甲基化和/或调节基因表达(包括转录沉默)的前列腺癌的诊断,分期和预后的新方法和组合物。 优选的诊断和/或预后核酸和蛋白质标志物包括以下中的至少一种:与锌指蛋白185(ZNF 185),前列腺分泌蛋白(PSP94),大疱性类天疱疮抗原相对应的差异(相对于良性组织)下调序列 (BPAG),supervillin(SVIL),富含脯氨酸的膜1(PRIMA1),TU3A,FLJ14084,KIAA1210,含有1(SORBS1)和C21orf63的Sorbin和SH3结构域; 和差异上调的序列MARCKS样蛋白(MLP)SRY(性别决定区Y)-box4(SOX4),脂肪酸结合蛋白5(FABP5),MAL2和Erg-2。